Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir versus placebo for pityriasis rosea
IRCT20210823052264N2Phase 3Completed
- Sponsor
- PNS Shifa
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aciclovir in pityriasis rosea (2 arms), sponsored by PNS Shifa. Primary endpoint: Clinical response. Started Feb 2023; status: completed.
02
Drugs
aciclovir
03
Conditions
pityriasis rosea
Beyond the preview
Go deeper on IRCT20210823052264N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N2.